Enhancement of doxorubicin concentration in the M5076 ovarian sarcoma cells by cucurbitacin E co-treatment

International Journal of Pharmaceutics

Volumn 383, Issue 1-2, 2010, Pages 186-191

  Sadzuka, Yasuyuki ^a,b   Hatakeyama, Haruna ^b   Sonobe, Takashi ^b  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Biochemical modulation; Cucurbitacin E; Doxorubicin; MRP; Permeability

Indexed keywords

ADENOSINE TRIPHOSPHATE; CUCURBITACIN; CUCURBITACIN E; DOXORUBICIN; GLYCOPROTEIN P; UNCLASSIFIED DRUG; VERLUKAST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENTIATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SARCOMA; SARCOMA CELL; SOLID TUMOR; TISSUE HOMOGENATE;

ANIMALS; CELL LINE, TUMOR; DOXORUBICIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; LEUKEMIA P388; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; OVARIAN NEOPLASMS; PROPIONATES; QUINOLINES; SARCOMA; TRITERPENES;

EID: 70449533776     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.08.040     Document Type: Article

References (39)

1. Bera T.K., Iavarone C., Kumar V., Lee S., Lee B., and Pastan I. MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer. Proc. Natl. Acad. Sci. 99 (2002) 6997-7002
2. Bertino R., Sawicki W.I., Lindquist C.A., and Gupta V.S. Schedule dependent antitumor effects of methotrexate and 5-fluorouracil. Cancer Res. 37 (1977) 327-328
3. Borst P., Evers R., Kool M., and Wijnholds J. The multidrug resistance protein family. Biochim. Biophy. Acta 1461 (1999) 347-357
4. 1 cell line and its resistant counterpart. Biochem. Pharmacol. 61 (2001) 61-66
5. Doyle L.A., and Ross D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22 (2003) 7340-7358
6. 4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem. Biophys Res. Commun. 208 (1995) 345-352
7. Goldstein L.J., Galski H., Fojo A., Willingham M., Lai A., Gazdar A., Pirker R., Green A., Crist W., and Brodeur G.M. Expression of a multidrug resistance gene in human cancers. J. Natl. Cancer Inst. 81 (1989) 116-124
8. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2 (2002) 48-58
9. Heijn M., Hooijberg J.H., Scheffer G.L., Szabo G., Westerhoff H.V., and Lankelma J. Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Biochim. Biophys. Acta 1326 (1997) 12-22
10. Hidalgo O.F., Gonzalez F., Gil A., Campbell W., Barrajon E., and Lacave A.J. 120 Hours simultaneous infusion of cisplatin and fluorouracil in metastatic breast cancer. Am. J. Clin. Oncol. 12 (1989) 397-401
11. Ichinose Y., Takahashi N., and Yano T. A phase III trial of oral tegafur and uracil plus cisplatin in patients with inoperable nonsmall cell lung cancer. Cancer 75 (1995) 2677-2680
12. Kool M., de Haas M., Scheffer G.L., Scheper R.J., Van Eijk M.J.T., Juijin J.A., Baas F., and Borst P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4 and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 57 (1997) 3537-3547
13. Kool M., van der Linden M., de Haas M., Baas F., and Borst P. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissue and cancer cells. Cancer Res. 59 (1999) 175-182
14. Kruh G.D., and Belinsky M.G. The MRP family of drug efflux pumps. Oncogene 22 (2003) 7537-7552
15. Kubota Y., Hosaka M., Fukushima S., and Kondo I. Prophylactic oral UFT therapy for superficial bladder cancer. Cancer 71 (1993) 1842-1845
16. Kuo M.T., Bao J., Furuichi M., Yamane Y., Gomi A., Savaraj N., Masuzawa T., and Ishikawa T. Frequent coexpression of MRP/GS-X pump and γ-glutamylcysteine synthetase mRNA in drug-resistant cells, untreated tumor cells, and normal mouse tissue. Biochem. Pharmacol. 55 (1998) 605-615
17. Litman T., Brangi M., Hudson E., Fetsch P., Abati A., Ross D.D., Miyake K., Resau J.H., and Bates S.E. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J. Cell Sci. 113 (2000) 2011-2021
18. Marbeuf-gueye C., Broxterman H.J., Dubru F., Priebe W., and Garnier-Suillerot A. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein- expressing cancer cells. Mol. Pharmacol. 53 (1998) 141-147
19. Nooter K., Westerman A.M., Flens M.J., Zaman G.J.R., Scheper R.J., van Wingerden K.E., Burger H., Oostrum R., Boersma T., Sonneveld P., Gratama J.W., Kok T., Eggermont A.M.M., Bosman F.T., and Stoter G. Expression of a multidrug resistance-associated protein (MRP) gene in human cancers. Clin. Cancer Res. 1 (1995) 1301-1310
20. O'Connel M.J. A phase III trial of 5-fluorouracil and leucovolin in the treatment of advanced colorectal cancer. Cancer 63 (1988) 1026-1030
21. 4 transport mediated by MRP/GS-X pump. Biochem. Biophys Res. Commun. 247 (1998) 859-863
22. Sadzuka Y., Mochizuki E., and Takino Y. Caffeine modulates the antitumor activity and toxic side effects of adriamycin. Jpn. J. Cancer Res. 84 (1993) 348-353
23. Sadzuka Y., Mochizuki E., Iwasaki A., Hirota S., and Takino Y. Caffeine enhances adriamycin antitumor activity in Ehrlich ascites carcinoma-bearing mice. Biol. Pharm. Bull. 18 (1995) 159-161
24. Sadzuka Y., Mochizuki E., and Takino Y. Mechanism of caffeine modulation of the antitumor activity of adriamycin. Toxicol. Lett. 7 (1995) 39-49
25. Sadzuka Y., Sugiyama T., Miyagishima A., Nozawa Y., and Hirota S. The effects of theanine, as a novel biochemical modulator, on the antitumor activity adriamycin. Cancer Lett. 105 (1996) 203-209
26. Sadzuka Y., Sugiyama T., and Sonobe T. Efficacies of tea components on doxorubicin induced antitumor activity and reversal of multidrug resistance. Toxicol. Lett. 114 (2000) 155-162
27. Sadzuka Y., Sugiyama T., Tanaka K., and Sonobe T. Inhibition of glutamate transporter by theanine enhances the therapeutic efficacy of doxorubicin. Toxicol. Lett. 121 (2001) 89-96
28. Sadzuka Y., Sugiyama T., Suzuki, and Sonobe T. Enhancement of the activity of doxorubicin by inhibition of glutamate transporter. Toxicol. Lett. 123 (2001) 159-167
29. Sadzuka Y., Hatakeyama H., Daimon T., and Sonobe T. Screening of biochemical modulator by tumor cell permeability of doxorubicin. Int. J. Pharm. 354 (2008) 63-69
30. Skovsgaard T. Transport and binding of daunorubicin, adriamycin and rubidazone in Ehrlich ascites tumor cells. Biochem. Pharmacol. 26 (1977) 215-222
31. Skovsgaard T. Carrier-mediated transport of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumor cells. Biochem. Pharmacol. 26 (1977) 1221-1227
32. Skovsgaard T. Mechanisms resistance to daunorubicin in Ehrlich ascites tumor cells. Cancer Res. 38 (1978) 1785-1791
33. Skovsgaard T. Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumor cells. Cancer Res. 38 (1978) 4722-4727
34. Siegfried J.M., Burke T.G., and Tritton T.R. Cellular transport of anthracyclines by passive diffusion: Implications for drug resistance. Biochem. Pharmacol. 34 (1985) 593-598
35. Slapak C.A., Lecerf J.M., Daniel J.C., and Stuart B.L. Energy-dependent accumulation of daunorubicin into subcellular compartments of human leukemia cells and cytoplasts. J. Biol. Chem. 267 (1992) 10638-10644
36. Sugiyama T., and Sadzuka Y. Enhancing effects of green tea components on the antitumor activity of adriamycin against M5076 ovarian sarcoma. Cancer Lett. 133 (1998) 19-26
37. Sugiyama T., and Sadzuka Y. Theanine and glutamate transporter inhibitors enhance the antitumor efficacy of chemotherapeutic agents. Biochim. Biophys. Acta 1653 (2003) 47-59
38. Sugiyama T., Sadzuka Y., and Sonobe T. Theanine, a specific glutamate derivative in green tea, reduces the adverse reactions of doxorubicin by changing the glutathione level. Cancer Lett. 212 (2004) 177-184
39. Zhang K., Yang E.B., Wong K.P., and Mack P. GSH, GSH-related enzymes and GS-X pump in relation to sensitivity of human tumor cell lines to chlorambucil and adriamycin. Int. J. Oncol. 14 (1999) 861-867